TG Therapeutics Inc (TGTX)
Cash conversion cycle
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| Days of inventory on hand (DOH) | days | 106.22 | — | — | — | — |
| Days of sales outstanding (DSO) | days | 84.37 | — | 75.79 | — | — |
| Number of days of payables | days | — | — | — | — | — |
| Cash conversion cycle | days | 190.59 | 0.00 | 75.79 | 0.00 | 0.00 |
December 31, 2023 calculation
Cash conversion cycle = DOH + DSO – Number of days of payables
= 106.22 + 84.37 – —
= 190.59
The cash conversion cycle (CCC) for TG Therapeutics Inc has displayed significant fluctuations over the past five years. In 2019, 2020, and 2022, the CCC was noted at 0.00 days, indicating that the company was efficiently managing its working capital and converting its inventory and receivables into cash quickly. However, in 2021, the CCC increased to 75.79 days, suggesting a delay in converting its resources into cash and potentially facing challenges in managing its working capital effectively.
The most recent data for 2023 shows a significant increase in the CCC to 190.59 days, which indicates a prolonged period for the company to convert its investments in inventory and receivables into cash. This notable increase may signal inefficiencies in the company's operations and working capital management, which could potentially lead to liquidity issues or constraints on its cash flow.
Overall, the fluctuating trend in the cash conversion cycle of TG Therapeutics Inc highlights the importance of closely monitoring working capital management practices to ensure operational efficiency and financial stability.
Peer comparison
Dec 31, 2023